SLDB Paul Herzich sells $11K worth of shares
Feb 19, 2025, 5:33 AM
-9.41%
What does SLDB do
Solid Biosciences, headquartered in Charlestown, Massachusetts, develops gene therapies for Duchenne muscular dystrophy and other cardiac diseases, employing 88 staff since its IPO on January 26, 2018. Their pipeline includes multiple gene therapy candidates and novel platform technologies.
Paul Herzich sold 2,688 shares of SLDB on 14 February at $3.96 per share, worth a total of $11K. They now own 18,388 SLDB shares, or a 13% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
